FORMULATION, DEVELOPMENT AND EVALUATION OF INTRAGASTRIC FLOATING INSITU GEL OF BRIVARACETAM

The aim of the present study was to establish and evaluate gastro retentive in situ gelling system of Brivaracetam using HPMC K100M, sodium alginate gelling polymer, calcium chloride and sodium citrate as a possible linking agent to treat bifocal epilepsy. In situ drug delivery systems that form polymeric formulations are in sol form before being administered to the body, but once administered, that under gelation in situ forms a gel. The composition of the gel depends on factors such as temperature fluctuations, pH changes and the presence of ions in which the drug is released continuously and in a controlled manner. In situ gelling floating systems were prepared by dissolving various concentrations of sodium alginate in distilled water, to which varying concentration of drug. The results show that formulas containing a combination of polymers (sodium alginate and HPMC K 100 M) show more delay in drug release than formulas based solely on sodium alginate by the same percentage. The F2 formulation was very well prepared for the ability to control long-term drug release with suitability in terms of pH and viscosity. The insitu-gel reflects expected, viscosity, drug content, pH, in vitro gelling capacity, in vitro floating capacity, water absorption capacity and continuous drug release. The gastro retentive Brivaracetam insitu gel can be prepared using a floating method to prolong the stay in the stomach and thus increase absorption. Keywords: Insitu gel, Gelation, Gastro Retentive Drug Delivery System, Epilepsy, Brivaraceta